These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32222203)

  • 1. Dolutegravir and neural tube defects: a new insight.
    Chouchana L; Pariente A; Pannier E; Tsatsaris V; Treluyer JM
    Lancet Infect Dis; 2020 Apr; 20(4):405-406. PubMed ID: 32222203
    [No Abstract]   [Full Text] [Related]  

  • 2. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.
    Raesima MM; Ogbuabo CM; Thomas V; Forhan SE; Gokatweng G; Dintwa E; Petlo C; Motswere-Chirwa C; Rabold EM; Tinker SC; Odunsi S; Malima S; Mmunyane O; Modise T; Kefitlhile K; Dare K; Letebele M; Roland ME; Moore CA; Modi S; Williamson DM
    N Engl J Med; 2019 Aug; 381(9):885-887. PubMed ID: 31329378
    [No Abstract]   [Full Text] [Related]  

  • 3. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.
    Zash R; Makhema J; Shapiro RL
    N Engl J Med; 2018 Sep; 379(10):979-981. PubMed ID: 30037297
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes to dolutegravir policy in several African countries.
    Nakkazi E
    Lancet; 2018 Jul; 392(10143):199. PubMed ID: 30043745
    [No Abstract]   [Full Text] [Related]  

  • 5. Dolutegravir for pregnant women living with HIV.
    Zipursky J; Loutfy M
    CMAJ; 2020 Mar; 192(9):E217-E218. PubMed ID: 32122978
    [No Abstract]   [Full Text] [Related]  

  • 6. Periconception dolutegravir use in women living with HIV and missed opportunities in maternal and child health.
    Myer L
    Lancet Child Adolesc Health; 2019 Oct; 3(10):669-671. PubMed ID: 31375312
    [No Abstract]   [Full Text] [Related]  

  • 7. Dolutegravir-induced extrapyramidal syndrome in a young woman.
    Dauby N; Bartholomé E; De Wit S
    AIDS; 2019 Mar; 33(4):763-764. PubMed ID: 30829747
    [No Abstract]   [Full Text] [Related]  

  • 8. Dolutegravir becomes first choice for HIV.
    Rahimi S
    Lancet Infect Dis; 2019 Sep; 19(9):937-938. PubMed ID: 31478520
    [No Abstract]   [Full Text] [Related]  

  • 9. Lessons from dolutegravir and neural tube defects.
    Abrams E; Myer L
    Lancet HIV; 2021 Jan; 8(1):e3-e4. PubMed ID: 33387476
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV Drug May Increase Risk of Neural Tube Birth Defects.
    Aschenbrenner DS
    Am J Nurs; 2019 Jan; 119(1):27. PubMed ID: 30589699
    [No Abstract]   [Full Text] [Related]  

  • 11. Dolutegravir-induced paresthesias.
    Fulco PP; Gomes DC; Bozymski KM
    AIDS; 2017 Jul; 31(11):1645-1646. PubMed ID: 28657966
    [No Abstract]   [Full Text] [Related]  

  • 12. Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.
    Wilson HI; Mapesi H
    Pan Afr Med J; 2020; 37():243. PubMed ID: 33552361
    [No Abstract]   [Full Text] [Related]  

  • 13. Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients.
    Rizzardo S; Lanzafame M; Lattuada E; Luise D; Vincenzi M; Tacconelli E; Vento S
    AIDS; 2019 Aug; 33(10):1673-1674. PubMed ID: 31305333
    [No Abstract]   [Full Text] [Related]  

  • 14. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.
    Romo ML; Patel RC; Edwards JK; Humphrey JM; Musick BS; Bernard C; Maina MW; Brazier E; Castelnuovo B; Penner J; Wyka K; Cardoso SW; Ly PS; Kunzekwenyika C; Cortés CP; Panczak R; Kelvin EA; Wools-Kaloustian KK; Nash D;
    Ann Intern Med; 2022 Jan; 175(1):84-94. PubMed ID: 34843382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir and weight gain: an unexpected bothering side effect?
    Menard A; Meddeb L; Tissot-Dupont H; Ravaux I; Dhiver C; Mokhtari S; Tomei C; Brouqui P; Colson P; Stein A
    AIDS; 2017 Jun; 31(10):1499-1500. PubMed ID: 28574967
    [No Abstract]   [Full Text] [Related]  

  • 16. Dolutegravir-induced neural tube defects in mice are folate responsive: Erratum.
    AIDS; 2024 Aug; 38(10):1607. PubMed ID: 38990319
    [No Abstract]   [Full Text] [Related]  

  • 17. [Dolutegravir (Tivicay) orally].
    J Pharm Belg; 2015 Sep; (3):47-8. PubMed ID: 26513835
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways.
    Zamek-Gliszczynski MJ; Zhang X; Mudunuru J; Du Y; Chen JL; Taskar KS; Huang J; Huang Y; Romach EH
    Drug Metab Dispos; 2019 Aug; 47(8):890-898. PubMed ID: 31167838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An implicit threat: dolutegravir-induced schizophrenic brief psychotic disorder and persistent cenesthopathy.
    Kanai O; Fujita K; Mio T
    AIDS; 2018 Nov; 32(18):2853-2854. PubMed ID: 30407255
    [No Abstract]   [Full Text] [Related]  

  • 20. Dolutegravir (Tivicay) for HIV.
    Med Lett Drugs Ther; 2013 Sep; 55(1426):77-9. PubMed ID: 24081387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.